vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and Thermon Group Holdings, Inc. (THR). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $147.3M, roughly 1.0× Thermon Group Holdings, Inc.). Thermon Group Holdings, Inc. runs the higher net margin — 12.4% vs -5.5%, a 17.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 9.6%). Thermon Group Holdings, Inc. produced more free cash flow last quarter ($13.1M vs $13.0M).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

Thermon Group Holdings, Inc. is a global provider of engineered thermal management solutions, specializing in heat tracing systems, heating cables, temperature monitoring controls, and associated installation support services. It serves core industrial segments including oil and gas, chemical processing, power generation, and food and beverage, with operating bases across North America, Europe, Asia-Pacific, and Latin America.

TARS vs THR — Head-to-Head

Bigger by revenue
TARS
TARS
1.0× larger
TARS
$151.7M
$147.3M
THR
Growing faster (revenue YoY)
TARS
TARS
+118.7% gap
TARS
128.4%
9.6%
THR
Higher net margin
THR
THR
17.9% more per $
THR
12.4%
-5.5%
TARS
More free cash flow
THR
THR
$91.0K more FCF
THR
$13.1M
$13.0M
TARS

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
TARS
TARS
THR
THR
Revenue
$151.7M
$147.3M
Net Profit
$-8.4M
$18.3M
Gross Margin
46.6%
Operating Margin
-5.3%
18.1%
Net Margin
-5.5%
12.4%
Revenue YoY
128.4%
9.6%
Net Profit YoY
63.8%
-1.3%
EPS (diluted)
$-0.17
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
THR
THR
Q4 25
$151.7M
$147.3M
Q3 25
$118.7M
$131.7M
Q2 25
$102.7M
$108.9M
Q1 25
$78.3M
Q4 24
$66.4M
Q3 24
$48.1M
Q2 24
$40.8M
Q1 24
$27.6M
Net Profit
TARS
TARS
THR
THR
Q4 25
$-8.4M
$18.3M
Q3 25
$-12.6M
$15.0M
Q2 25
$-20.3M
$8.6M
Q1 25
$-25.1M
Q4 24
$-23.1M
Q3 24
$-23.4M
Q2 24
$-33.3M
Q1 24
$-35.7M
Gross Margin
TARS
TARS
THR
THR
Q4 25
46.6%
Q3 25
46.4%
Q2 25
44.1%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
TARS
TARS
THR
THR
Q4 25
-5.3%
18.1%
Q3 25
-12.2%
16.4%
Q2 25
-21.6%
10.8%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
TARS
TARS
THR
THR
Q4 25
-5.5%
12.4%
Q3 25
-10.6%
11.4%
Q2 25
-19.8%
7.9%
Q1 25
-32.1%
Q4 24
-34.8%
Q3 24
-48.7%
Q2 24
-81.6%
Q1 24
-129.4%
EPS (diluted)
TARS
TARS
THR
THR
Q4 25
$-0.17
$0.55
Q3 25
$-0.30
$0.45
Q2 25
$-0.48
$0.26
Q1 25
$-0.64
Q4 24
$-0.57
Q3 24
$-0.61
Q2 24
$-0.88
Q1 24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
THR
THR
Cash + ST InvestmentsLiquidity on hand
$417.3M
$46.9M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$538.7M
Total Assets
$562.2M
$816.7M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
THR
THR
Q4 25
$417.3M
$46.9M
Q3 25
$401.8M
$29.7M
Q2 25
$381.1M
$36.5M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
TARS
TARS
THR
THR
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
TARS
TARS
THR
THR
Q4 25
$343.4M
$538.7M
Q3 25
$335.1M
$515.2M
Q2 25
$332.6M
$509.3M
Q1 25
$342.5M
Q4 24
$224.5M
Q3 24
$237.5M
Q2 24
$252.2M
Q1 24
$275.2M
Total Assets
TARS
TARS
THR
THR
Q4 25
$562.2M
$816.7M
Q3 25
$534.6M
$778.2M
Q2 25
$495.0M
$765.3M
Q1 25
$500.8M
Q4 24
$377.0M
Q3 24
$376.3M
Q2 24
$376.8M
Q1 24
$349.3M
Debt / Equity
TARS
TARS
THR
THR
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
THR
THR
Operating Cash FlowLast quarter
$19.3M
$18.0M
Free Cash FlowOCF − Capex
$13.0M
$13.1M
FCF MarginFCF / Revenue
8.6%
8.9%
Capex IntensityCapex / Revenue
4.2%
3.3%
Cash ConversionOCF / Net Profit
0.98×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
THR
THR
Q4 25
$19.3M
$18.0M
Q3 25
$18.3M
$7.4M
Q2 25
$-29.4M
$10.7M
Q1 25
$-20.7M
Q4 24
$-22.2M
Q3 24
$-8.7M
Q2 24
$-14.4M
Q1 24
$-37.8M
Free Cash Flow
TARS
TARS
THR
THR
Q4 25
$13.0M
$13.1M
Q3 25
$16.3M
$4.4M
Q2 25
$-30.4M
$8.3M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
TARS
TARS
THR
THR
Q4 25
8.6%
8.9%
Q3 25
13.8%
3.3%
Q2 25
-29.6%
7.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
TARS
TARS
THR
THR
Q4 25
4.2%
3.3%
Q3 25
1.6%
2.3%
Q2 25
1.0%
2.2%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
TARS
TARS
THR
THR
Q4 25
0.98×
Q3 25
0.50×
Q2 25
1.25×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TARS
TARS

Segment breakdown not available.

THR
THR

Other$73.7M50%
Transferred At Point In Time$56.1M38%
Transferred Over Time$17.5M12%

Related Comparisons